IRIS
RONCATO, Rossana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.375
AS - Asia 1.678
EU - Europa 911
SA - Sud America 283
Continente sconosciuto - Info sul continente non disponibili 248
AF - Africa 60
OC - Oceania 4
Totale 6.559
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.214
SG - Singapore 802
CN - Cina 345
IT - Italia 282
BR - Brasile 220
HK - Hong Kong 186
VN - Vietnam 104
DE - Germania 102
RU - Federazione Russa 99
FR - Francia 92
GB - Regno Unito 69
CA - Canada 61
IN - India 57
IE - Irlanda 48
FI - Finlandia 46
BD - Bangladesh 39
KR - Corea 39
NL - Olanda 30
MX - Messico 26
UA - Ucraina 22
AR - Argentina 21
AT - Austria 20
ES - Italia 19
TR - Turchia 18
CH - Svizzera 16
NI - Nicaragua 15
SE - Svezia 15
TG - Togo 15
PL - Polonia 14
JP - Giappone 13
CZ - Repubblica Ceca 12
HN - Honduras 11
ID - Indonesia 11
CO - Colombia 10
CR - Costa Rica 9
EC - Ecuador 9
PK - Pakistan 9
SA - Arabia Saudita 9
ZA - Sudafrica 9
TT - Trinidad e Tobago 8
VE - Venezuela 8
IQ - Iraq 7
TN - Tunisia 7
GT - Guatemala 6
JM - Giamaica 6
MA - Marocco 6
PR - Porto Rico 6
AE - Emirati Arabi Uniti 5
CW - ???statistics.table.value.countryCode.CW??? 5
EG - Egitto 5
GP - Guadalupe 5
KE - Kenya 5
LT - Lituania 5
AU - Australia 4
DK - Danimarca 4
PE - Perù 4
BE - Belgio 3
BO - Bolivia 3
CL - Cile 3
DZ - Algeria 3
JO - Giordania 3
OM - Oman 3
RO - Romania 3
SC - Seychelles 3
SV - El Salvador 3
UY - Uruguay 3
AO - Angola 2
AZ - Azerbaigian 2
CI - Costa d'Avorio 2
CY - Cipro 2
GE - Georgia 2
KZ - Kazakistan 2
MY - Malesia 2
NP - Nepal 2
PH - Filippine 2
PY - Paraguay 2
QA - Qatar 2
TH - Thailandia 2
UZ - Uzbekistan 2
AG - Antigua e Barbuda 1
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
DM - Dominica 1
EE - Estonia 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
KY - Cayman, isole 1
MT - Malta 1
MZ - Mozambico 1
NG - Nigeria 1
NO - Norvegia 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 6.311
Salva come PNG Salva come JPEG
Città #
Ashburn 346
Singapore 336
Council Bluffs 293
San Jose 285
Hong Kong 184
Chicago 136
Los Angeles 136
Beijing 134
Boardman 116
Fairfield 70
Chandler 68
Santa Clara 65
Dallas 58
Salt Lake City 58
Lauterbourg 56
New York 50
Dublin 47
Houston 45
Hefei 40
Munich 40
Wilmington 40
Seoul 39
Woodbridge 38
Cambridge 32
Seattle 32
Elk Grove Village 30
Ho Chi Minh City 30
Hanoi 29
Milan 29
Buffalo 28
Frankfurt am Main 26
Montreal 26
North Bergen 26
Redondo Beach 24
Tampa 23
Helsinki 22
Phoenix 22
The Dalles 22
Denver 21
Rome 21
São Paulo 20
London 17
Nuremberg 17
Genoa 16
Miami 16
Zurich 16
Brooklyn 15
Lomé 15
Orem 15
Ann Arbor 14
Managua 14
Dearborn 13
Pune 13
Turku 13
Vienna 13
Ogden 12
Tokyo 12
Warsaw 12
Amsterdam 11
Miano 11
Atlanta 10
Brno 10
Chennai 10
Stockholm 10
Hyderabad 9
Naples 9
Princeton 9
Sterling 9
Arezzo 8
Dulles 8
Lappeenranta 8
Poplar 8
Redmond 8
Shanghai 8
Brasília 7
Detroit 7
Jacksonville 7
Lancaster 7
Mumbai 7
Toronto 7
Udine 7
Ankara 6
Guangzhou 6
Guatemala City 6
Guayaquil 6
Las Vegas 6
Louisville 6
Manchester 6
Mexico City 6
Pittsburgh 6
Portsmouth 6
San José 6
Shenzhen 6
Belluno 5
Belo Horizonte 5
Charlotte 5
Des Moines 5
Düsseldorf 5
Guarulhos 5
Haiphong 5
Totale 3.688
Salva come PNG Salva come JPEG
Nome #
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment 561
Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC) 197
Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation 171
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer 155
Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity 150
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 143
The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines 140
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 136
Abstract PD10-01: Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach 132
mHealth Apps Available in Italy to Support Health Care Professionals in Antimicrobial Stewardship Implementation: Systematic Search in App Stores and Content Analysis 130
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome 129
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 127
DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients 123
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 122
SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy 122
CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients 115
Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk 115
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study 112
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future 111
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice 110
IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm 104
FARMAPRICE: A Pharmacogenetic Clinical decision support system for precise and Cost-Effective Therapy 103
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer 100
The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity 97
Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy (Cell Death & Disease, (2022), 13, 4, (398), 10.1038/s41419-022-04741-9) 96
Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy 96
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 94
Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring 93
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring 93
Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis 91
The challenge of molecular selection in liver-limited metastatic colorectal cancer for surgical resection: a systematic review and meta-analysis in the context of current and future approaches 91
Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer 91
Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection? 90
A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients 88
Implementation of preemptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? 84
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 83
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions 83
The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure 80
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype 79
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 79
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach 76
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines 76
Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study 76
Therapeutic drug monitoring for the cancer patient: challenges and opportunities 75
Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy 73
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma 72
Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers 72
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS) 71
Genetic biomarkers for hepatocellular cancer risk in a caucasian population 70
Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice 70
Pharmacovigilance, drug interactions, pharmacogenetics and therapeutic drug monitoring of anticancer agents: a valuable support for clinical practice 70
European association for clinical pharmacology and therapeutics young clinical pharmacologists working group: a cornerstone for the brighter future of clinical pharmacology 69
Clinical relevance and methodological approach for the assessment of drug–drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF) 68
Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine 64
Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation 61
Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategy 55
Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients 54
Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI 52
Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider 46
Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug–gene interactions 45
DPYD and UGT1A1 Genotype‐Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant‐Specific Impact on Treatment Intensity and Toxicity 41
Pharmacogenetic testing in Italy: results of a nationwide survey by the Joint Working Group for the pharmacogenetics implementation in Italy 39
Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity – A secondary analysis of the PREPARE trial 36
Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study 30
Pharmacokinetics of therapies approved for spinal muscular atrophy: A narrative review of current evidence 29
A systematic literature review of economic evaluations of setmelanotide 27
Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence 24
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape 22
Editorial: Innovations in pharmacogenomics: embracing diversity and clinical application 22
Pharmacogenetic Implementation Studies—Lessons Learned From the PREPARE Study 20
Beyond Conventional Monoclonals: Novel Antibody Formats and Derivatives as the Next Frontier in Cancer Therapy 15
DPYD c.85 T > C, DPYD c.496 A>G, and DPYD c.2194 G>A and severe toxicity to fluoropyrimidines in PREPARE and Alpe-DPD trials. An original study and meta-analysis 14
Treatment-Resistant Depression: Esketamine Is Promising, but Personalized Medicine Including Pharmacogenetic Testing Should Come First 9
Totale 6.559
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.376
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.376
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202254 0 0 0 0 2 2 11 0 4 10 14 11
2022/2023318 9 3 4 77 59 70 0 22 45 4 9 16
2023/2024339 31 19 11 4 39 40 21 15 19 31 25 84
2024/20251.233 53 87 42 37 85 69 91 57 126 99 221 266
2025/20263.159 456 408 403 223 320 206 307 95 164 214 243 120
2026/20271.087 174 177 262 419 55 0 0 0 0 0 0 0
Totale 6.559